👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

US FDA proposes standardized testing to detect asbestos in talc products

Published 12/26/2024, 10:42 AM
Updated 12/26/2024, 02:41 PM
© Reuters. FILE PHOTO: A bottle of Johnson and Johnson Baby Powder is seen in a photo illustration taken in New York, February 24, 2016. REUTERS/Mike Segar/Illustration/File Photo
JNJ
-

(Reuters) - The U.S. Food and Drug Administration is proposing that cosmetic products containing talc should be tested using standardized methods to detect asbestos, a potential contaminant, according to documents posted on the federal register on Thursday.

WHY IT'S IMPORTANT

Asbestos, a known human carcinogen, can be injurious to consumers if found in talc-containing cosmetic products as there is no established "safe level" threshold for exposure to the substance.

If finalized, the rule can help protect consumers from harmful exposure to asbestos, leading to fewer illnesses such as lung and ovarian cancers, the health regulator said.

CONTEXT

Johnson & Johnson (NYSE:JNJ) is facing lawsuits from more than 62,000 claimants, who have alleged that the company's baby powder and other talc products were contaminated with asbestos and caused ovarian and other cancers.

The healthcare giant seeks to resolve the claims through an approximately $10 billion settlement in bankruptcy. It has denied the allegations and called its products safe.

In its proposed rule, the FDA would require manufacturers to test a sample of each batch of a talc-containing cosmetic product for asbestos by using methods such as polarized light and transmission electron microscopy, which produces images by illuminating samples with an electron beam.

If the manufacturer fails to comply with testing and record-keeping requirements, the proposed rule allows the FDA to declare that product as adulterated under the Federal Food, Drug, and Cosmetic Act.

WHAT'S NEXT

© Reuters. FILE PHOTO: A Johnson & Johnson banner is displayed on the front of the New York Stock Exchange (NYSE) in New York City, in New York City, U.S., December 5, 2023.  REUTERS/Brendan McDermid/File Photo

The FDA is seeking comments on the proposed rule from the public and industry representatives for the next 90 days before finalizing the requirements.

(This story has been refiled to change the image, with no changes to text)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.